RecruitingPhase 2Phase 3NCT07075718
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Sponsor
Glaukos Corporation
Enrollment
610 participants
Start Date
Jun 12, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Diagnosis of open-angle glaucoma or ocular hypertension in the study eye
Exclusion Criteria3
- Prior incisional glaucoma surgery in the study eye
- Prior argon laser trabeculoplasty (ALT) in the study eye
- Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Interventions
DRUGGen 2 Travoprost Intracameral Implant
travoprost
DRUGTimolol eye drops 0.5%
timolol 0.5%
PROCEDURESham Procedure
sham implant administration
OTHERPlacebo eye drops
artificial tears
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07075718
Related Trials
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
NCT043545451 location
Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma
NCT066829621 location
Automated Applanation Tonometry - Updated
NCT072983561 location
Alcon Hydrus Stent Implantation - Long Term Follow up After 8 Years
NCT074607911 location
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
NCT072176781 location